search
Back to results

Feasibility Trial of ValenTx Endo Bypass System

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
ValenTx Endo Bypass System
Sponsored by
ValenTx, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female between 18 and 55 years of age
  • >=35 kg/m2 and <= 50 kg/m2, with or without comorbid conditions(s).
  • Documented failure with non-surgical weight loss methods
  • Willing to comply with study procedures and visit schedule
  • Willing and able to provide Informed Consent

Exclusion Criteria:

  • Pregnancy or intention of becoming pregnant within the study duration.
  • Endoscopic lesions such as important hiatal hernia, gastric or duodenal ulcer, atresias or stenosis, polyps of the stomach.
  • Subject with potential upper gastrointestinal bleeding such as esophageal or gastric varices, Mallory-Weis syndrome or congenital or acquired intestinal telangiectasia.
  • Past history of esophageal or gastric/GI surgery, obstruction, adhesive peritonitis, or large hiatal hernia (> 3 cm).
  • IBS, unexplained intermittent vomiting, severe abdominal pain or chronic constipation within 60 days of study day 1
  • Unexplained anaemia, Pancreatitis, Portal hypertension, Esophagitis or Barrett's esophagus, known gallstones or anomalies of the GI tract
  • Any bodily infections within 30 days of study day 1.
  • Prolonged steroid use
  • Hep C or HIV positive
  • Known allergies to any of the device materials
  • Use of weight loss medication or an investigational drug or device within 2 months prior to enrolment and throughout the study period.
  • Recent or ongoing cancer, history of severe renal, hepatic, cardiovascular or pulmonary disease or transplants
  • Inability to tolerate anti-inflammatory medications
  • Evidence of psychiatric problems or dietary habits that would contraindicate study treatment;
  • Active drug or alcohol addiction within 12 months of enrolment and throughout the study duration.
  • Prior history of inflammatory diseases of the GI tract, (e.g., esophagitis, varices, gastric or duodenal ulceration, or Crohn's disease; congenital or acquired GI anomalies, e.g., bowel strictures)
  • Ongoing treatment with anticoagulants, steroids, aspirin, NSAIDs, or other gastric irritants within 1 month prior to enrollment and throughout the study period.
  • Participation in previous (within 60 days of study day 1) or ongoing clinical trial or current or past usage (within 60 days of study day 1) of investigation drug or device.

Sites / Locations

  • Hospital San Jose Tec de Monterrey

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Device

Arm Description

Outcomes

Primary Outcome Measures

Device-related adverse events

Secondary Outcome Measures

Device performance

Full Information

First Posted
September 21, 2010
Last Updated
March 15, 2016
Sponsor
ValenTx, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01207804
Brief Title
Feasibility Trial of ValenTx Endo Bypass System
Official Title
A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ValenTx, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese patients.
Detailed Description
This is a single center open label feasibility study to evaluate the safety, efficacy and performance of the ValenTx Endo Bypass system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
ValenTx Endo Bypass System
Other Intervention Name(s)
ValenTx, Endo Bypass System, EBS
Intervention Description
Patient is implanted with device and followed for 12 weeks
Primary Outcome Measure Information:
Title
Device-related adverse events
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Device performance
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female between 18 and 55 years of age >=35 kg/m2 and <= 50 kg/m2, with or without comorbid conditions(s). Documented failure with non-surgical weight loss methods Willing to comply with study procedures and visit schedule Willing and able to provide Informed Consent Exclusion Criteria: Pregnancy or intention of becoming pregnant within the study duration. Endoscopic lesions such as important hiatal hernia, gastric or duodenal ulcer, atresias or stenosis, polyps of the stomach. Subject with potential upper gastrointestinal bleeding such as esophageal or gastric varices, Mallory-Weis syndrome or congenital or acquired intestinal telangiectasia. Past history of esophageal or gastric/GI surgery, obstruction, adhesive peritonitis, or large hiatal hernia (> 3 cm). IBS, unexplained intermittent vomiting, severe abdominal pain or chronic constipation within 60 days of study day 1 Unexplained anaemia, Pancreatitis, Portal hypertension, Esophagitis or Barrett's esophagus, known gallstones or anomalies of the GI tract Any bodily infections within 30 days of study day 1. Prolonged steroid use Hep C or HIV positive Known allergies to any of the device materials Use of weight loss medication or an investigational drug or device within 2 months prior to enrolment and throughout the study period. Recent or ongoing cancer, history of severe renal, hepatic, cardiovascular or pulmonary disease or transplants Inability to tolerate anti-inflammatory medications Evidence of psychiatric problems or dietary habits that would contraindicate study treatment; Active drug or alcohol addiction within 12 months of enrolment and throughout the study duration. Prior history of inflammatory diseases of the GI tract, (e.g., esophagitis, varices, gastric or duodenal ulceration, or Crohn's disease; congenital or acquired GI anomalies, e.g., bowel strictures) Ongoing treatment with anticoagulants, steroids, aspirin, NSAIDs, or other gastric irritants within 1 month prior to enrollment and throughout the study period. Participation in previous (within 60 days of study day 1) or ongoing clinical trial or current or past usage (within 60 days of study day 1) of investigation drug or device.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto Rumbaut, MD
Organizational Affiliation
Hospital San Jose Tec
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital San Jose Tec de Monterrey
City
Monterrey
ZIP/Postal Code
64710
Country
Mexico

12. IPD Sharing Statement

Learn more about this trial

Feasibility Trial of ValenTx Endo Bypass System

We'll reach out to this number within 24 hrs